Phosphodiesterase type 5 inhibitors were initially approved for the treatment of erectile dysfunction in men and were later suggested for some systemic disorders, mostly due to their possible beneficial effects on endothelial functions. Paradoxically, though, phosphodiesterase type 5 inhibitors may have some life-threatening effects, for which there is weak evidence, it appears that they are associated with cardiovascular problems such as myocardial infarction and stroke. This study aimed to investigate the acute effects of tadalafil citrate on the cardiovascular system by evaluating serum oxidative status and paraoxonase-1 activity. Sera of 36 patients with erectile dysfunction were analyzed for total antioxidant status, total oxidant status and paraoxonase-1, before and after the administration of tadalafil citrate. Pre-and post-tadalafil citrate serum levels of total antioxidants, total oxidants and paraoxonase-1 were 1.1 ± 0.0 and 1.6 ± 0.0 lmol H 2 O 2 equiv l , respectively (Po0.0001 for all results). This preliminary study confirmed that tadalafil citrate exerts a beneficial acute effect on the cardiovascular system by reducing serum levels of oxidative stress and increasing serum levels of paraoxonase-1.
Introduction
Although phosphodiesterase type 5 (PDE5) inhibitors were initially approved for the treatment of erectile dysfunction (ED) in men, their clinical spectrum has been expanding beyond the treatment of ED in consideration of the enormous advances that have been undertaken during the past decade. Preliminary studies showed that the benefits of PDE5 inhibitors were not restricted to human sexuality, particularly ED. In fact, these could potentially be used to treat certain systemic disorders, such as cardiovascular conditions and diabetes mellitus, due to their beneficial effects on endothelial functions, depression, pulmonary hypertension, preeclampsia, inflammation, chronic heart failure and renal insufficiency, and hypertensive disorders. [1] [2] [3] [4] [5] PDE5 inhibitors may even be used in the treatment of cancer, as they contribute to the induction of apoptotic mechanisms. 6 However, controversy remains about the tolerance of PDE5 inhibitors, especially regarding possible life-threatening acute cardiovascular system (CVS) and neurological system events, such as myocardial infarction (MI) and stroke. 7, 8 It is well known that oxidative stress leads to impaired vasodilatation of the coronary, pulmonary and peripheral vascular beds. 9 There is limited information about the effect of PDE5 inhibitors on serum oxidative mechanisms, although it is well known that they can restore endothelial nitric oxide (NO), resulting in vasodilatation and the inhibition of chemotaxis and platelet aggregation. 10 In some of these studies, sildenafil citrate was shown to have protective effects on oxidative stress by inhibiting free radical formation and supporting antioxidant redox systems; this reduction in oxidative stress is the supposed reason behind the improvement in endothelial function. 11, 12 However, to the best of our knowledge, the effect of PDE5 inhibitors on paraoxonase, which is closely related to serum oxidative status and cardiovascular and endothelial functions, has not yet been reported.
High-density lipoprotein (HDL) exerts its antiatherogenic effects by preventing the oxidation of low-density lipoprotein (LDL). Two enzymes of HDL, paraoxonase-1 (PON-1) and platelet-activating factor acetylhydrolase, have been shown to prevent the formation of oxidized LDL in vitro. PON-1 is an HDL-associated antioxidant enzyme with paraoxonase, arylesterase and dyazoxonase activities. [13] [14] [15] Human serum paraoxonase activity is a strong predictor of coronary artery disease (CAD), as shown by reports of low serum paraoxonase activity in patients with CAD; low serum paraoxonase activity also has an effect on certain conditions associated with enhanced atherogenesis, such as hypercholesterolemia and diabetes. 15, 16 It has also been noted that PON-1 is involved in the acute phase of the MIs. 17 In this study, we investigated the acute effects of tadalafil citrate at peak serum level on the CVS by evaluating serum oxidative status and PON-1 enzyme activity.
Patients and methods

Subjects
This study included 36 patients (aged 37-59 years old, mean ± s.d. 49.5 ± 6.5 years) who were being followed up at the Department of Urology with clinically documented mild to severe ED, were in a stable monogamous relationship with a female partner and had recently been recommended PDE5 inhibitor treatment. The study was approved by institutional review board of Harran University and was therefore performed in accordance with the Declaration of Helsinki Principles. The participants were informed about the study protocol and written consent was obtained before the initiation of the study. All patients were evaluated with a detailed sexual history, physical examination, blood chemistry and endocrine assay, in addition to color Doppler ultrasonography during pharmacologically induced and sexually stimulated erection. Patients who suffered angina during intercourse or unstable angina, who displayed any other evidence of recently diagnosed CAD, poorly controlled blood pressure or orthostatic hypotension, congestive heart failure, arrhythmia, significant renal or hepatic dysfunction or anemia, and those older than 60 years were excluded. Moreover, patients who were receiving any medication for any reason and those who had undergone any pelvic surgery were also excluded. All blood samples for determination of total antioxidant status (TAS), total oxidant status (TOS) and PON-1 activity were collected from the subjects just before and 2 h after the ingestion of 20 mg oral tadalafil citrate (Cialis; Lilly Inc., Istanbul, Turkey), as peak plasma levels of the drug are achieved at approximately 120 min after administration. During this period, subjects were kept at rest in a polyclinic setting and were allowed to consume only water. Blood sample collections were performed in an air-conditioned medical consultation room at temperatures varying from 23 to 25 1C.
Measurement of total oxidant and antioxidant status
The analysis of TOS was performed using an automated colorimetric measurement method. This assay is based on the oxidation of ferrous ion to ferric ion in the presence of various oxidant species in acidic medium and the measurement of ferric ion using xylenol orange. Within-and between-batch precision values were lower than 3%. The results were expressed as mmol H 2 O 2 equiv l À1 . TAS was measured using an automated measurement method in which a hydroxyl radical is produced through the Fenton reaction and potent colored dianisidinyl radical cations are produced in the reaction medium of the assay. As samples are added to this reaction medium, their antioxidant capacity against these colored potent free radical reactions is measured. This assay had excellent precision values, with within-and between-batch precision values being lower than 3%. The results were expressed as mmol Trolox equiv l À1 .
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Measurement of paraoxonase-1 activity Paraoxonase-1 activity was determined using paraoxon as a substrate and measuring increases in the absorbance at 412 nm, which indicates the formation of 4-nitrophenol. Briefly, PON-1 activity was measured at 25 1C by adding 50 ml serum to 1 ml Tris-HCl buffer (100 mM at pH 8.0) containing 2 mM CaCl 2 and 5.5 mM paraoxon. The rate of generation of 4-nitrophenol was determined at an absorbance of 412 nm. Enzymatic activity was calculated using the molar extinction coefficient 17 100 M À1 cm À1 .
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Statistical analysis
Results were expressed as mean±s.d. for all continuous variables. Differences between pre-and post-medication measurements were assessed using paired sample t-tests. Po0.05 was considered the threshold for statistical significance. 
Discussion
The PDE5 inhibitor prototype sildenafil citrate has been on the market since 1998, with the participation of two other similar drugs (Verdanafil Hcl and tadalafil citrate). Patients with ED have been using these drugs in increasing numbers since then. Studies on the beneficial effects of PDE5 inhibitors on endothelial functions and their contribution to vascular repair have provided justification for the expansion of the indication spectrum. 11, 12, 20, 21 Paradoxically, the associations of PDE5 inhibitors usage and some life-threatening events, such as acute MI and stroke, in connection with some disorders, such as cardiac arrhythmias, hypo/hypertension, are related to the cardiac and neurovascular systems. 7, 8 Nevertheless, recent reports strongly suggest that there is no increase in the incidence of acute MI or death rates during sexual activity while using PDE5 inhibitors. 8, 22, 23 Although weak, there is evidence of an association of sildenafil citrate with cardiac arrhythmias. 23 The issue of tolerance remains important because a great proportion of PDE5 inhibitor users are older and have some other cardiovascular and neurovascular problems; moreover, it is certain that sexual activity exerts extra pressure on these systems, which is why all patients with ED receive strict recommendations for an evaluation by a cardiologist. 24 Thus, this study aimed to document the acute effects of tadalafil citrate at peak serum levels on the vascular system, by evaluating serum oxidative/antioxidative status and PON-1 enzyme activity. Tadalafil citrate was chosen for this study because it has the longest half-life in all PDE5 inhibitors, which, we believe, makes it ideal for possible prophylactic (rather than on-demand) indications in the future. The issue of tolerance will become increasingly important for long-term users.
It has been suggested that oral vasoactive pharmacotherapy, such as the use of PDE5 inhibitor drugs, may provide vasculoprotective benefits in patients with cardiovascular disease or vasculogenic ED. 25 The reduced serum oxidative stress engendered by these drugs is thought to be the cornerstone of the mechanism behind the protective effects. Moreover, oxidative stress has been shown to have a role in the development and progression of atherosclerosis. 26 One placebo-controlled study found that 100 mg sildenafil citrate had a beneficial effect on the serum oxidative status of subjects without any health problems; the effect lasted for about a day. 11 Another study reported the same conclusion in an animal model of passive-smoking-induced ED. 12 Our results on the oxidative status of patients with ED support these findings for tadalafil citrate; additionally, although we did not measure data more than 2 h after drug administration, we propose that the reduction in serum oxidative stress may last more than a day, given that tadalafil citrate has a longer serum half-life than sildenafil citrate. This beneficial effect of PD5 on serum oxidative status may also be supported empirically by the finding that the antioxidant vitamin E enhances levels of circulating NO and thus may improve erectile function, with potential for a synergistic effect with PDE5 inhibitors. 27 Conversely, in a recent clinical study, Burnett et al.
25 found no effect of sildenafil citrate (50-100 mg) on the serum oxidative status of diabetic patients with ED receiving a daily dose for 4 weeks. However, the authors mentioned that this effect may have been due to an ineffective dosage, and suggested three times daily sildenafil citrate dosing for an adequate effect on serum biomarkers. It should also be kept in mind that all three PDE5 inhibitors currently available for prescription showed similar oxidative activity in a study focused on human monocytes. 28 However, to the best of our knowledge, this is the first clinical study evaluating the relationship between tadalafil citrate and serum oxidative/ antioxidative status that has shown a decrease in TOS and an increase in TAS values. This effect on serum oxidative status may be due to PDE5 inhibitors preventing the activity and expression of Effects of tadalafil on serum oxidative status A Verit et al nicotinamide adenine dinucleotide phosphate oxidase by enhancing cGMP levels, which would lead to a decrease in the formation of reactive oxygen species and an increase in antioxidant enzymes.
11
The antioxidant enzyme PON-1 is reported to have a significant effect on the occurrence of MIs, as low serum PON-1 activity within a few hours of the onset of cardiac ischemic chest pain has been detected in survivors of MI. 17 The release of PON-1 is associated with acute coronary syndromes, as confirmed by studies using meta-analysis. 29 Furthermore, as to chronic systemic vascular diseases, serum levels of PON-1 are inversely related to the number of diseased coronary vessels and the severity of hypertension and hyperlipidemia. 30, 31 PON-1 is also implicated in the mechanism of atherosclerosis. 15 Thus, in our opinion, the evaluation of the activity of this enzyme in this preliminary study may be important for patients using tadalafil citrate in the context of evaluation of acute and chronic CVS risk. Furthermore, the PON-1 serum levels of patients with ED had already been shown to be lower than those of a control group, an effect attributed to the co-incidence of atherogenesis and ED. 32 We found that tadalafil citrate increased PON-1 serum levels, which may indicate a positive effect on vascular health. We propose tadalafil citrate is ideal for regular usage in the treatment of both ED and CVS disorders, with daily or everyother-day administration, in the future. Given the importance of systemic disease, PD5 inhibitor usage will probably be forced toward to the vascular wellbeing with the results further studies.
In conclusion, although suspicions about the possible complications of PDE5 inhibitor usage have ceased in light of the recent reports, clinicians still have doubts regarding the tolerance of these drugs, especially for patients with ED and CVS comorbidity. Although the 120 min time span between measurements in this study could be considered a limitation, the results of this preliminary study point to a beneficial acute effect of tadalafil citrate on CVS through the reduction of serum levels of oxidative stress and the increase of serum PON-1 activity. Still, further long-term clinical studies on tadalafil citrate use, especially studies involving atrisk groups such as hypertensive and CAD patients with ED, should continue to examine this issue.
